Scott L. Burrows - Jan 15, 2025 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRE	Stock Option (Right to Buy)	Award	$0	+95.5K		$0.00	95.5K	Jan 15, 2025	Common Stock	95.5K	$21.66	Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.